CA2396739A1 - Compositions for treating abnormalities in glomerular filtration, patent ductus arteriosus and osteoporosis - Google Patents

Compositions for treating abnormalities in glomerular filtration, patent ductus arteriosus and osteoporosis Download PDF

Info

Publication number
CA2396739A1
CA2396739A1 CA002396739A CA2396739A CA2396739A1 CA 2396739 A1 CA2396739 A1 CA 2396739A1 CA 002396739 A CA002396739 A CA 002396739A CA 2396739 A CA2396739 A CA 2396739A CA 2396739 A1 CA2396739 A1 CA 2396739A1
Authority
CA
Canada
Prior art keywords
group
patient
compound
amino acids
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002396739A
Other languages
English (en)
French (fr)
Inventor
Krishna G. Peri
Sylvain Chemtob
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre Hospitalier Universitaire Saint Justine
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2396739A1 publication Critical patent/CA2396739A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Water Treatment By Sorption (AREA)
  • Water Treatment By Electricity Or Magnetism (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pipe Accessories (AREA)
  • Flanged Joints, Insulating Joints, And Other Joints (AREA)
CA002396739A 1999-12-06 2000-12-06 Compositions for treating abnormalities in glomerular filtration, patent ductus arteriosus and osteoporosis Abandoned CA2396739A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45548399A 1999-12-06 1999-12-06
US09/455,483 1999-12-06
PCT/CA2000/001445 WO2001042281A1 (en) 1999-12-06 2000-12-06 Compositions for treating abnormalities in glomerular filtration, patent ductus arteriosus and osteoporosis

Publications (1)

Publication Number Publication Date
CA2396739A1 true CA2396739A1 (en) 2001-06-14

Family

ID=23808998

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002396739A Abandoned CA2396739A1 (en) 1999-12-06 2000-12-06 Compositions for treating abnormalities in glomerular filtration, patent ductus arteriosus and osteoporosis

Country Status (12)

Country Link
US (1) US7442763B2 (https=)
EP (1) EP1244693B1 (https=)
JP (1) JP2003516417A (https=)
AT (1) ATE298346T1 (https=)
AU (1) AU784630B2 (https=)
CA (1) CA2396739A1 (https=)
DE (1) DE60020997T2 (https=)
ES (1) ES2246915T3 (https=)
MX (1) MXPA02005626A (https=)
NZ (1) NZ520762A (https=)
WO (1) WO2001042281A1 (https=)
ZA (1) ZA200205795B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040235749A1 (en) * 1999-09-15 2004-11-25 Sylvain Chemtob G-protein coupled receptor antagonists
MXPA02005626A (es) 1999-12-06 2004-09-10 Pital Sainte Justine H Composiciones para el tratamiento de filtracion glomerular, conductos arteriosos y osteoporosis del paciente.
EP1467738A1 (en) * 2001-10-08 2004-10-20 Medical Research Council Use of prostaglandin e synthase inhibitors, or ep2 or ep4 receptor antagonists, in the treatment of a pathological condition of the uterus
JP2005511562A (ja) * 2001-10-31 2005-04-28 メディカル リサーチ カウンシル 月経困難症及び月経過多の治療のためのプロスタグランジンレセプターｅｐ２及び／又はｅｐ４のアンタゴニスト
CN1662551A (zh) * 2002-05-23 2005-08-31 瑟瑞技术公司 前列腺素e2受体亚型ep4的拮抗肽
EP1878741A3 (en) * 2002-05-23 2008-02-20 Theratechnologies Inc. Antagonistic peptides of prostaglandin E2 receptor subtype EP4
US7414029B2 (en) 2002-05-23 2008-08-19 Theratechnologies, Inc. Antagonistic peptides of prostaglandin E2 receptor subtype EP4
WO2004073589A2 (en) * 2003-02-24 2004-09-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor prostaglandin e2 ep4 (prostaglandin e2 ep4)
US8618054B2 (en) * 2004-05-05 2013-12-31 Valorisation-Rechereche Société en Commandite Interleukin-1 receptor antagonists, compositions, and methods of treatment
US20150126573A1 (en) 2012-05-09 2015-05-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for prevention or treatment of chronic obstructive pulmonary disease
BR112023018676A2 (pt) 2021-03-18 2023-10-10 Seagen Inc Conjugado anticorpo-fármaco, composição farmacêutica, métodos de tratamento de uma doença ou condição e de um câncer, e, composição de conjugado ligante-fármaco

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9019120D0 (en) * 1990-09-01 1990-10-17 Beecham Group Plc Novel compounds
US5508384A (en) * 1992-09-10 1996-04-16 New York University Polypeptide derived from a popamine receptor, and compositions and methods thereof
BR9406652A (pt) * 1993-03-05 1996-09-10 Cytel Corp Composição
US5869281A (en) 1993-06-25 1999-02-09 Merck Frosst Canada Inc. DNA encoding prostaglandin receptor FP
US5605814A (en) * 1993-08-31 1997-02-25 Merck Frosst Canada Inc. DNA encoding human prostaglandin receptor EP2
JPH09504174A (ja) * 1993-10-29 1997-04-28 インサイト ファーマシューティカルズ，インク． プロテアーゼネキシン１変異体を含むキメラ蛋白
EP0756604A1 (en) * 1994-04-22 1997-02-05 THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services Melanoma antigens
US5866679A (en) * 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
WO1996006856A1 (en) * 1994-08-31 1996-03-07 Robert Webber Dopamine receptor peptides and anti-peptide antibodies
WO1996019233A2 (en) * 1994-12-12 1996-06-27 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain, inflammation and spasm
JPH11514207A (ja) 1995-01-25 1999-12-07 シーオーアール・セラピューティックス・インコーポレーテッド 組換えｃ１４０リセプター、そのアゴニストおよびアンタゴニスト、並びに該リセプターをコードする核酸
US5877155A (en) * 1995-03-17 1999-03-02 The Research Foundation Of State University Of New York Mimotopes and anti-mimotopes of human platelet glycoprotein Ib/IX
US6117839A (en) * 1995-06-07 2000-09-12 Gensci Regeneration Sciences, Inc. Bone stimulating factor
WO1997034621A1 (en) * 1996-03-21 1997-09-25 Cytel Corporation Hla-a2.1 binding peptides and their uses
JP2001501601A (ja) * 1996-09-12 2001-02-06 メルク エンド カンパニー インコーポレーテッド 前立腺ガンの治療において有用な共役体
US5955575A (en) * 1997-12-22 1999-09-21 Hopital Sainte-Justine Antagonists of G-protein-coupled receptor
AUPP320998A0 (en) * 1998-04-27 1998-05-21 Walter And Eliza Hall Institute Of Medical Research, The Tyrosine phosphatase IA-2 T-cell epitopes
US6984719B1 (en) * 1998-09-17 2006-01-10 Hospital Sainte-Justine Peptide antagonists of prostaglandin F2α receptor
US20040235749A1 (en) * 1999-09-15 2004-11-25 Sylvain Chemtob G-protein coupled receptor antagonists
MXPA02005626A (es) 1999-12-06 2004-09-10 Pital Sainte Justine H Composiciones para el tratamiento de filtracion glomerular, conductos arteriosos y osteoporosis del paciente.

Also Published As

Publication number Publication date
AU784630B2 (en) 2006-05-18
AU2134001A (en) 2001-06-18
EP1244693A1 (en) 2002-10-02
NZ520762A (en) 2005-02-25
US20030017988A1 (en) 2003-01-23
ATE298346T1 (de) 2005-07-15
DE60020997D1 (de) 2005-07-28
EP1244693B1 (en) 2005-06-22
WO2001042281A1 (en) 2001-06-14
DE60020997T2 (de) 2006-05-24
ZA200205795B (en) 2007-01-31
JP2003516417A (ja) 2003-05-13
MXPA02005626A (es) 2004-09-10
ES2246915T3 (es) 2006-03-01
US7442763B2 (en) 2008-10-28

Similar Documents

Publication Publication Date Title
JP5502480B2 (ja) 生物活性ペプチド及びその使用方法
JP4346650B2 (ja) メタスチン誘導体およびその用途
JP4786047B2 (ja) ペプチド誘導体
JP5355561B2 (ja) 生物活性ペプチドおよびその使用方法
CA2260767A1 (en) Fas ligand-like protein, its production and use
KR20230036156A (ko) α4β7 인테그린 티오에테르 펩티드 길항제
EP1244693B1 (en) Compositions for treating abnormalities in glomerular filtration, patent ductus arteriosus and osteoporosis
US20040023853A1 (en) Antagonistic peptides of prostaglandin E2 receptor subtype EP4
AU2018227345B2 (en) Compositions and methods for improving sexual function
JP2006506327A5 (https=)
ES2393462T3 (es) Péptido útil para inhibir la actividad del receptor de prosta-glandina F2X
US9155795B2 (en) CXCR4 receptor compounds
AU701677B2 (en) Recombinant C140 receptor and its agonists and antagonists
WO1997011091A1 (fr) Nouveaux composes peptidiques et leurs compositions medicinales
CA2342960C (en) G protein-coupled receptor antagonists
WO2001089582A1 (en) Preventives and remedies for pulmonary hypertension
JP2003516417A5 (https=)
JP2008013436A (ja) 血管形成促進剤
US7414029B2 (en) Antagonistic peptides of prostaglandin E2 receptor subtype EP4
JPH10271997A (ja) 新規Ｆａｓリガンド様タンパク質およびそのＤＮＡ
CA3246325A1 (en) Urokinase-type plasminogen activator receptor-binding peptides and methods of use
WO2020000063A1 (en) Rheumatoid arthritis treatment
EP1878741A2 (en) Antagonistic peptides of prostaglandin E2 receptor subtype EP4
JP2000159795A (ja) ペプチド誘導体
JP2002355077A (ja) カスパーゼ３阻害剤

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued